299 results on '"Shaw, James W."'
Search Results
2. Administering selected subscales of patient-reported outcome questionnaires to reduce patient burden and increase relevance: a position statement on a modular approach
3. Estimating the minimally important difference for the EQ-5D-5L and EORTC QLQ-C30 in cancer
4. A scoping review of the use of minimally important difference of EQ-5D utility index and EQ-VAS scores in health technology assessment
5. Modelling Health State Utilities as a Transformation of Time to Death in Patients with Non-Small Cell Lung Cancer
6. Correction to: A Review of the Use of EQ-5D for Clinical Outcome Assessment in Health Technology Assessment, Regulatory Claims, and Published Literature
7. A Methodological Study to Compare Alternative Modes of Administration With Value EQ-5D Using Preference-Elicitation Techniques
8. A Review of Meaningful Change Thresholds for EORTC QLQ-C30 and FACT-G Within Oncology
9. International Society for Quality of Life Research commentary on the US Food and Drug Administration draft guidance for industry on core patient-reported outcomes in cancer clinical trials
10. Assessing the Content Validity of Preference-Based Measures in Cancer
11. Equivalence testing of a newly developed interviewer-led telephone script for the EORTC QLQ-C30
12. General population normative data for the EQ-5D-3L in the five largest European economies
13. Adapting preference-based utility measures to capture the impact of cancer treatment-related symptoms
14. A Comparison of Generic and Condition-Specific Preference-Based Measures Using Data From Nivolumab Trials: EQ-5D-3L, Mapping to the EQ-5D-5L, and European Organisation for Research and Treatment of Cancer Quality of Life Utility Measure-Core 10 Dimensions
15. Mapping EQ-5D-3L to EQ-5D-5L
16. Does recall period matter? Comparing PROMIS ® physical function with no recall, 24-hr recall, and 7-day recall
17. A comparison of self-rated health using EQ-5D VAS in the United States in 2002 and 2017
18. A Review of the Use of EQ-5D for Clinical Outcome Assessment in Health Technology Assessment, Regulatory Claims, and Published Literature
19. Assessing the Content Validity of Preference-Based Measures in Cancer
20. The value of immunotherapy for survivors of stage IV non-small cell lung cancer: patient perspectives on quality of life
21. United States Valuation of EQ-5D-5L Health States Using an International Protocol
22. Modelling Health State Utilities as a Transformation of Time to Death in Patients with Non-Small Cell Lung Cancer
23. A Q-TWiST Analysis Comparing Nivolumab and Therapy of Investigator’s Choice in Patients with Recurrent/Metastatic Platinum-Refractory Squamous Cell Carcinoma of the Head and Neck
24. US Valuation of the EQ-5D Health States: Development and Testing of the D1 Valuation Model
25. Valuations of EQ-5D Health States: Are the United States and United Kingdom Different?
26. Comparison of Preferences and Data Quality between Discrete Choice Experiments Conducted in Online and Face-to-Face Respondents
27. General population reference values for the Functional Assessment of Cancer Therapy‐Lung and PROMIS ‐29
28. sj-docx-1-mdm-10.1177_0272989X231171912 – Supplemental material for Comparison of Preferences and Data Quality between Discrete Choice Experiments Conducted in Online and Face-to-Face Respondents
29. sj-docx-2-mdm-10.1177_0272989X231171912 – Supplemental material for Comparison of Preferences and Data Quality between Discrete Choice Experiments Conducted in Online and Face-to-Face Respondents
30. Integrating the patient voice with clinician reports to identify a hepatocellular carcinoma-specific subset of treatment-related symptomatic adverse events
31. EP1029: EVALUATION OF WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT IN MODERATE-TO-SEVERE ULCERATIVE COLITIS PARTICIPANTS TREATED WITH OZANIMOD IN THE PHASE 3 TRUE NORTH STUDY
32. The effect of chronic conditions on stated preferences for health
33. Annual Incremental Health Benefit Costs and Absenteeism Among Employees With and Without Rheumatoid Arthritis
34. Effects of aromatase inhibition versus gonadectomy on hippocampal complex amyloid pathology in triple transgenic mice
35. Relative Efficiency of the EQ-5D, HUI2, and HUI3 Index Scores in Measuring Health Burden of Chronic Medical Conditions in a Population Health Survey in the United States
36. The Determinants of Life Expectancy: An Analysis of the OECD Health Data
37. Validation of Stopwatch Measurements of Erection Duration against Responses to the Sexual Encounter Profile and International Index of Erectile Function in Patients Treated with a Phosphodiesterase Type 5 Inhibitor
38. A Median Model for Predicting United States Population-Based EQ-5D Health State Preferences
39. Equivalence testing of a newly developed interviewer-led telephone script for the EORTC QLQ-C30
40. Impact of JIA on parents’ work absences
41. A Patient-Based Utility Measure of Health for Clinical Trials of Cancer Therapy Based on the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire
42. sj-docx-2-mdm-10.1177_0272989X211003569 – Supplemental material for United States Utility Algorithm for the EORTC QLU-C10D, a Multiattribute Utility Instrument Based on a Cancer-Specific Quality-of-Life Instrument
43. sj-docx-1-mdm-10.1177_0272989X211003569 – Supplemental material for United States Utility Algorithm for the EORTC QLU-C10D, a Multiattribute Utility Instrument Based on a Cancer-Specific Quality-of-Life Instrument
44. United States Utility Algorithm for the EORTC QLU-C10D, a Multiattribute Utility Instrument Based on a Cancer-Specific Quality-of-Life Instrument
45. Development And Validation Of A Voice Script For Telephone Administration Of THE EORTC QLQ-C30
46. A comparison of EQ-5D index scores derived from the US and UK population-based scoring functions
47. Racial/ethnic differences in preferences for the EQ-5D health states: results from the U.S. valuation study
48. Onychomycosis: Health-Related Quality of Life Considerations
49. Comparison of Two Health-Promotion Programs for Older Workers
50. Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United States
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.